Outsourced Manufacturing Operations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Outsourced Manufacturing Operations


Pharmaceutical Technology
Volume 35, pp. s46-s49

Supply-chain visibility

Improved supply-chain visibility supports both integrated and collaborative planning. While organizations should not get hung up on establishing absolute real-time data, there is a need to have accurate and up-to-date information.

The challenges. Traditionally, a mix of enterprise resource planning (ERP) or material resource planning (MRP) and Excel spreadsheets are used to communicate demand and transactions, but these have deficiencies. ERP systems often don't interface well between organizations. They can be inflexible for supporting scenario and contingency base planning. These systems are compensated for by Excel files, which can themselves be manually adapted with out-of-date, incomplete, or inaccurate information. The challenge is to give key parties visibility on what is happening and what is likely to happen next in the simplest manner possible.

What can make a difference? The marketplace for information-technology (IT) systems is evolving rapidly. Demand sensing and cloud technologies are being increasingly used to share the latest information, to automatically predict trends, and to link parties in the network—relatively painlessly—without the need for large and costly IT infrastructure. The use of these systems can cost effectively make a step-change in the quality of information available.

Specifically, demand sensing can be used to more accurately predict shortterm demand that is less well predicted through integrated planning, but still drives the majority of stock. This approach can improve an organization's chances of shaping demand to match planned supply, reduce stock uncertainty as short-term demand patterns are reduced and, through the use of tailored algorithms, allow for forecasts to remain accurate.

In addition, cloud technologies are increasingly being used to facilitate information sharing between organizations that are not plugged into the same global or regional IT system. These technologies tend to be based on Internet interfaces that multiple parties can access and use to communicate through, with access granted at various levels as required.

Improving supply-chain visibility on its own doesn't resolve visibility issues, but it does facilitate integrated and collaborative planning, and allows organizations and parts of organizations to be working from one data set.

Example. A leading healthcare manufacturer developed an end-to-end order visibility tool. It enabled the full order-to-delivery picture to be viewed both across the organization and by supply-chain partners. The tool highlighted exceptions orders using red flags so that priorities could be addressed, thus improving customer service whilst reducing inventory.

At the 2011 European Supply Chain and Logistics summit, several organizations, including P&G, explained the benefits of using techniques such as demand sensing. This approach was acknowledged to improve the accuracy of short-term forecasts, which, in turn, can help companies make a 20% improvement in stock levels. Innovative contracts

Enhanced contracts can align real benefits for both organizations. To consider when forming contracts are: flexibility, capacity, and delivery and stocking policy, with the goal of improving jointly agreed-upon measures.

The challenges. Given normal business focus and procurement targets, it is common to accept the best product cost based on standard service and management terms. Costplus model contracts are regularly signed without any clear understanding of what the supplier is providing for the increased management fee.

What can make a difference? For strategic relationships, it is beneficial to develop contracts that include targets and rewards for measures other than straight product costs. These should include realistic but challenging targets for the supplier, as well as what is strategically important for the pharmaceutical contractor in terms of overall landed cost, cash flow, and service.

Conclusion

Pharmaceutical manufacturers have a great opportunity to get more value from their contract manufacturing relationships. From the authors' experience, by focusing on key initiatives, companies can anticipate more than 20% improvement in inventory alone, as well as benefits in terms of improving supply-chain responsiveness and agility, and exploiting jointly identified initiatives to the benefit of all parties.

James Wright and Malcolm Horsley are supply chain and pharmaceutical experts, respectively, at PA Consulting Group.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
15%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here